| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Specific molecular targets of Shancigusin I have not been extensively characterized. As a natural phenylpropanoid from Cremastra appendiculata, it may share biological activities with other phenylpropanoids, including antioxidant, anti-inflammatory, antimicrobial, or cytotoxic properties. Cremastra appendiculata is used in traditional medicine, suggesting potential therapeutic activities. However, specific molecular targets have not been identified in the available literature. Further studies are needed to elucidate its mechanism of action.
|
|---|---|
| ln Vitro |
In vitro activity data for Shancigusin I are limited in the published literature. The compound has been primarily characterized as a natural product from Cremastra appendiculata. As a phenylpropanoid, it may exhibit various biological activities including antioxidant, anti-inflammatory, or cytotoxic effects in cell-based assays. However, detailed in vitro activity data including IC₅₀ values have not been extensively published. Further studies are needed to characterize its biological activities.
|
| ln Vivo |
In vivo activity data for Shancigusin I are not available in the published literature. The compound has been primarily characterized as a natural product from Cremastra appendiculata. No in vivo pharmacological studies have been reported for this compound. Given its presence in Cremastra appendiculata, a plant used in traditional medicine, it may contribute to the therapeutic effects of the plant. However, dedicated in vivo studies for this compound have not been conducted or reported.
|
| Enzyme Assay |
In vitro assays for Shancigusin I are not extensively documented. As a phenylpropanoid, potential assays could include antioxidant activity evaluation using DPPH or ABTS radical scavenging assays, anti-inflammatory activity by measuring cytokine production in immune cells, or cytotoxicity screening against cancer cell lines using MTT or SRB assays. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC.
|
| Cell Assay |
In vitro cellular assays for Shancigusin I are not extensively documented. Potential cellular assays could include evaluation of antioxidant activity in cell-based oxidative stress models, anti-inflammatory activity in macrophages or other immune cells, or cytotoxicity in cancer cell lines. Cells are treated with the compound and cell viability, reactive oxygen species levels, or cytokine production is measured. The compound is soluble in DMSO at 100 mg/mL (168.19 mM) with ultrasonic warming to 60°C. Storage: 4°C, protect from light.
|
| Animal Protocol |
In vivo animal experiments for Shancigusin I have not been reported in the published literature. The compound has been studied primarily as a natural product from Cremastra appendiculata. No animal studies have been conducted to evaluate its pharmacological effects, toxicity, or pharmacokinetics. Further research would be required to investigate its potential therapeutic applications in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Shancigusin I have not been characterized. The compound has a molecular weight of 594.56 g/mol and a molecular formula of C₂₈H₃₄O₁₄. As a large glycosylated phenylpropanoid, it is expected to have limited oral bioavailability due to its size and hydrophilic nature. The compound may undergo deglycosylation in the gastrointestinal tract. Solubility: DMSO 100 mg/mL (168.19 mM) with ultrasonic warming to 60°C. Storage: 4°C, protect from light.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Shancigusin I has not been extensively documented. As a natural phenylpropanoid from Cremastra appendiculata, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Shancigusin I (CAS# 1435488-35-9, molecular formula C₂₈H₃₄O₁₄, molecular weight 594.56) is a natural phenylpropanoid from Cremastra appendiculata. No clinical trials or regulatory approvals have been identified. Solubility: DMSO 100 mg/mL. Storage: 4°C, protect from light.
|
| Molecular Formula |
C28H34O14
|
|---|---|
| Molecular Weight |
594.56
|
| Exact Mass |
594.194
|
| CAS # |
1435488-35-9
|
| PubChem CID |
102582111
|
| Appearance |
White to off-white solid powder
|
| Density |
1.543±0.06 g/cm3(Predicted)
|
| Boiling Point |
888.7±65.0 °C(Predicted)
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
42
|
| Complexity |
858
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C1=CC(=CC=C1COC(=O)/C=C/C2=CC=C(C=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
CYFVSRSBPGWWOF-YHUVOSSASA-N
|
| InChi Code |
InChI=1S/C28H34O14/c29-11-18-21(32)23(34)25(36)27(41-18)39-16-6-1-14(2-7-16)5-10-20(31)38-13-15-3-8-17(9-4-15)40-28-26(37)24(35)22(33)19(12-30)42-28/h1-10,18-19,21-30,32-37H,11-13H2/b10-5+/t18-,19-,21-,22-,23+,24+,25-,26-,27-,28-/m1/s1
|
| Chemical Name |
[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl (E)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (168.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6819 mL | 8.4096 mL | 16.8192 mL | |
| 5 mM | 0.3364 mL | 1.6819 mL | 3.3638 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
